Paraneoplastic Cerebellar Syndrome and Optic Neuritis With Anti-CV2 Antibodies

Sayette, Vincent de La; Bertran, Françoise; Honnorat, Jérôme; Schaeffer, S.; Iglesias, S.; Defer, Gilles

doi:10.1001/archneur.55.3.405

Cited by 72 publications

(21 citation statements)

References 23 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is important considering that the detection of an onconeural antibody indicates the presence of an underlying tumour. Successful treatment of the tumour is the main factor associated with stabilisation or improvement of PNS [12,13], such as we report in the present case. However, this response is not always associated with a change in the levels of the onconeural antibodies, as previously reported [14].…”

supporting

confidence: 67%

Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies

et al. 2007

View full text Add to dashboard Cite

supporting

confidence: 67%

Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies

et al. 2007

View full text Add to dashboard Cite

“…9,10,19 Although some patients simultaneously harbor anti-CV2 and anti-Hu antibodies, this study clearly shows that the anti-CV2-related neuropathy differs from that seen in the anti-Hu syndrome. The anti-Hu-related neuropathy is usually SSN, 3,4 whereas the anti-CV2 neuropathy is a subacute sensory motor, sometimes predominantly motor, symmetrical neuropathy.…”

Section: Discussionmentioning

confidence: 66%

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy

Antoine¹,

et al. 2001

View full text Add to dashboard Cite

“…This response of the neurological syndrome to tumour therapy has been documented in single case reports. [17][18][19] In a study of 50 patients with PCD, seven experienced an improvement in their neurological status following antitumour therapy, however, the observed effect was not statistically significant. 20 Similarly in 73 patients with PEM/PSN, antitumour therapy was associated with a higher, but not statistically significant, probability of experiencing a successful neurological outcome.…”

Section: Discussionmentioning

confidence: 97%

A follow up study of patients with paraneoplastic neurological disease in the United Kingdom

Candler

Hart²,

Barnett³

et al. 2004

Journal of Neurology, Neurosurgery & Psychiatry

129

View full text Add to dashboard Cite

Objectives: To examine the range of clinical phenotypes, tumour associations, relevant investigations, response to therapy and outcome in a large series of non-selected patients with paraneoplastic neurological disease (PND) affecting the central nervous system (CNS) in the United Kingdom. Methods: Data were obtained on patients either through direct referral or through the British Neurological Surveillance Unit (BNSU) from February 2000 to January 2001. Physicians were asked to supply information about age and sex of patients, presenting neurological syndromes, the basis of the diagnosis of PND, any associated malignancy, and treatment. Case notes were reviewed and follow up data obtained where possible one year after notification. Results: A total of 63 patients (48 females, 15 males) were identified, 48 through the BNSU and 15 through direct referral. Of these 52 were diagnosed as having definite PND, 10 probable PND, and 1 possible PND. The median age of onset of PND was 66 years (range 30-80 years) and only 7 patients (11%) were less than 50 years at presentation. In 53 patients (84%) the PND preceded the diagnosis of cancer. Paraneoplastic sensory neuronopathy, paraneoplastic encephalomyelitis, and paraneoplastic cerebellar degeneration (PCD) were the most common syndromes reported. The benefit of magnetic resonance imaging in the diagnosis of the disease was limited, while fluorodeoxyglucose positron emission tomography was shown to be useful for the detection of an occult malignancy in 10 out of 14 patients. Antineuronal antibodies were positive in 44/57 (77%) of cases. The following tumours were diagnosed: small cell lung cancer (30%), breast cancer (14%), ovarian cancer (8%), non-small cell lung cancer (8%), Hodgkin's lymphoma (6%), other (16%). With the exception of PCD associated with mesothelioma all other tumours diagnosed in these patients had been previously documented as being associated with PND. Only treatment of the tumour was found to be associated with a stable or improved neurological outcome at last follow up (Fisher's exact test = 4.7, p,0.03). Median survival time was 43 months (95% CI 28 to 57) from onset of neurological disease as calculated using the Kaplan-Meier survival analysis. Conclusions: PND has a striking female preponderance usually affecting patients in their sixth decade and above. The median survival in our study was 43 months. The majority of patients with PND are not known to have cancer at the time of diagnosis. Our study confirms the importance of diagnosing and treating the underlying tumour.

show abstract

Paraneoplastic Cerebellar Syndrome and Optic Neuritis With Anti-CV2 Antibodies

Cited by 72 publications

References 23 publications

Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies

Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy

A follow up study of patients with paraneoplastic neurological disease in the United Kingdom

Contact Info

Product

Resources

About